Consensus-based care recommendations for adults with myotonic dystrophy type 1. by A.T. 3. et al.
REVIEW OPEN ACCESS
Consensus-based care recommendations for
adults with myotonic dystrophy type 1
Tetsuo Ashizawa, MD, Cynthia Gagnon, PhD, William J. Groh, MD, MPH, Laurie Gutmann, MD,
Nicholas E. Johnson, MD, Giovanni Meola, MD, Richard Moxley III, MD, Shree Pandya, DPT, Mark T. Rogers, MD,
Ericka Simpson, MD, Nathalie Angeard, PhD, Guillaume Bassez, MD, PhD, Kiera N. Berggren, MA, MS,
Deepak Bhakta, MD, Marco Bozzali, MD, Ann Broderick, MD, MS, Janice L.B. Byrne, MD, Craig Campbell, MD,
Edith Cup, PhD, John W. Day, MD, PhD, Elisa De Mattia, PT, Denis Duboc, MD, Tina Duong, MPT, PhDc,
Katy Eichinger, PhD, Anne-Berit Ekstrom, MD, PhD, Baziel van Engelen, MD, PhD, Belen Esparis, MD,
Bruno Eymard, MD, Marla Ferschl, MD, Shahinaz M. Gadalla, MD, PhD, Benjamin Gallais, PhD,
Todd Goodglick, MD, Chad Heatwole, MD, James Hilbert, MS, Venessa Holland, MD, MPH,
Marie Kierkegaard, PhD, Wilma J. Koopman, NP, PhD, Kari Lane, RD, Daphne Maas, PT, MSc, Ami Mankodi, MD,
Katherine D. Mathews, MD, Darren G. Monckton, PhD, David Moser, PhD, Saman Nazarian, MD, PhD,
Linda Nguyen, MD, Peg Nopoulos, MD, Richard Petty, MD, Janel Phetteplace, MS, Jack Puymirat, MD, PhD,
Subha Raman, MD, Louis Richer, PhD, Elisabetta Roma, MD, Jacinda Sampson, MD, PhD,
Valeria Sansone, MD, PhD, Benedikt Schoser, MD, Laurie Sterling, MS, Jeffrey Statland, MD,
S.H. Subramony,MD, Cuixia Tian,MD, CareniñaTrujillo, RN,MSN,Gordon Tomaselli,MD, Chris Turner,MD, PhD,
Shannon Venance, MD, PhD, Aparajitha Verma, MD, Molly White, MA, and Stefan Winblad, PhD on behalf of
the Myotonic Dystrophy Foundation
Neurology: Clinical Practice December 2018 vol. 8 no. 6 507-520 doi:10.1212/CPJ.0000000000000531
Correspondence
Dr. White
molly.white@myotonic.org
Abstract
Purpose of review
Myotonic dystrophy type 1 (DM1) is a severe, progressive genetic
disease that aﬀects between 1 in 3,000 and 8,000 individuals
globally. No evidence-based guideline exists to inform the care of
these patients, andmost do not have access to multidisciplinary care
centers staﬀed by experienced professionals, creating a clinical care
deﬁcit.
Recent findings
The Myotonic Dystrophy Foundation (MDF) recruited 66 in-
ternational clinicians experienced in DM1 patient care to develop
consensus-based care recommendations. MDF created a 2-step methodology for the project using
elements of the Single Text Procedure and the Nominal Group Technique. The process generated
a 4-page Quick Reference Guide and a comprehensive, 55-page document that provides clinical
care recommendations for 19 discrete body systems and/or care considerations.
Summary
The resulting recommendations are intended to help standardize and elevate care for this
patient population and reduce variability in clinical trial and study environments.
Described as “one of the more variable diseases found in medicine,”myotonic dystrophy type
1 (DM1) is an autosomal dominant, triplet-repeat expansion disorder that aﬀects somewhere
between 1:3,000 and 1:8,000 individuals worldwide.1 There is a modest association between
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increased repeat expansion and disease severity, as evidenced
by the average age of onset and overall morbidity of the
condition. An expansion of over 35 repeats typically indicates
an unstable and expanding mutation. An expansion of 50
repeats or higher is consistent with a diagnosis of DM1. DM1
is a multisystem and heterogeneous disease characterized by
distal weakness, atrophy, and myotonia, as well as symptoms
in the heart, brain, gastrointestinal tract, endocrine, and re-
spiratory systems. Symptoms may occur at any age. The
severity of the condition varies widely among aﬀected indi-
viduals, even among members of the same family.
Comprehensive evidence-based guidelines do not currently
exist to guide the treatment of DM1 patients. As a result, the
international patient community reports varied levels of care
and care quality, and diﬃculty accessing care adequate to
manage their symptoms, unless they have access to multi-
disciplinary neuromuscular clinics.
Consensus-based care recommendations can help standard-
ize and improve the quality of care received by DM1 patients
and assist clinicians who may not be familiar with the sig-
niﬁcant variability, range of symptoms, and severity of the
disease. Care recommendations can also improve the land-
scape for clinical trial success by eliminating some of the
inconsistencies in patient care to allow more accurate un-
derstanding of the beneﬁt of potential therapies.
Methods
The Myotonic Dystrophy Foundation (MDF) recruited
clinicians from the United States, United Kingdom, Canada,
and Europe who have experience in the treatment of indi-
viduals living with DM1 to develop consensus-based care
recommendations.
The project included a Steering Committee of 10 and a total
Working Group of 66 clinical professionals, with additional
support from the US Centers for Disease Control and Pre-
vention and the services of a facilitation ﬁrm, Interaction
Associates (San Francisco), that provided the meeting facil-
itation necessary to execute the Nominal Group Technique
portion of the methodology. MDF provided project design,
development, and management support.
To streamline the project timeline and lower project cost,
MDF developed a 2-phased, consensus-building method-
ology using components of the Single Text Procedure2 and
the Nominal Group Technique.3–5 These facilitation
approaches were selected because they could be eﬀective
within the context of the limited clinical care data available
for DM1, the clinical content already available, and the
complexities of working across a large, multinational group
of experts.
The Working Group was divided into 8 Study Area sub-
committees, each led by a Steering Committee chair who
identiﬁed members for his or her Study Area. The Study
Areas were each assigned several body systems aﬀected by
myotonic dystrophy.
Working Group subcommittee members began the
consensus-building project by creating the background
reading lists for their Study Areas. These reading lists were
reﬁned as the project moved forward, and the Study Area lists
serve as the bibliography for the ﬁnal Consensus-based
Recommendations.
The Single Text Procedure, using a single document as
a starting point to incorporate the input and contributions of
stakeholders, was used to begin the consensus-building eﬀort.
In this process, stakeholders add, subtract, and reﬁne a draft
text that becomes the foundation for a ﬁnal ratiﬁed
document.
Working with MDF, Margaret Wahl, RN, organized the draft
document, drawing substantially from care content in the
MDF Toolkit developed by the MDF’s Scientiﬁc and Med-
ical Advisory Committee, as well as several other key
references.6–9 MDF circulated the draft document to
Working Group members, along with other materials
designed to help coordinate the editing and revision process.
Working Group members read the draft content for their
Study Areas and provided Study Area-speciﬁc recom-
mendations. MDF aggregated all the revisions and sugges-
tions into a single updated document. Recommendations in
conﬂict were circulated to the group for discussion and re-
solved through serial conference calls.
The Steering Committee reviewed the aggregated document,
oﬀered revisions, and then returned it to the full Working
Group. This process was repeated until the Steering Com-
mittee and Working Group achieved consensus.
Sixty-six Steering Committee and Working Group members
then met for a face-to-face summit that involved the second
phase of the project, the Nominal Group Technique.
The Nominal Group Technique is a face-to-face, structured
group meeting led by an experienced facilitator. Participants
engage in a serial discussion of each revised, updated, or
newly-generated recommendation led by the facilitator.
MDF engaged 7 professional facilitators from Interaction
Associates to drive consensus building in Study Area sub-
committee meetings at the summit.
Comprehensive evidence-based
guidelines do not currently exist to
guide the treatment of DM1 patients.
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MDF then created an updated document aggregating the
changes from the facilitated discussions, and the full Working
Group went through the same facilitated process again with
the new document, which concluded the Nominal Group
Technique portion of the process.
MDF then created a postsummit, updated document based
on full-group feedback at the meeting. This version was used
to conduct a ﬁnal series of rounds of edit solicitation and
updated document review through email and conference call.
These eﬀorts led to the ﬁnal consensus-based care recom-
mendations and Quick Reference Guide for Adults with
DM1, which were completed in mid-2017. The Quick Ref-
erence Guide is provided as an appendix, and the full docu-
ment is available online (appendix e-1, links.lww.com/CPJ/
A53). Both feature ﬂowcharts and other infographics for ease
of use.
Results
See full recommendations at Neurology.org/cp.
Life threatening symptoms—Clinical
care recommendations
 Surgery, anesthesia, and pain
s See MDF’s Practical Suggestions for the Anesthetic
Management of a Myotonic Dystrophy Patient
(myotonic.org/clinical-resources) for anesthesia risks
and recommendations before any surgeries or
procedures requiring anesthesia.
s DM1 patients have adverse reactions to medications
used for anesthesia and analgesia, including opioids;
interactions of the cardiac, respiratory, muscle, and
CNS manifestations in each DM1 patient can lead to
a variety of untoward responses, including mortality,
before, during, and after surgery.
s Serious adverse events to anesthesia and opioids can
occur throughout the course of DM1 and have been
reported in patients whose DM1 symptoms were mild.
s Intellectual impairment, cognitive dysfunction, and/
or hypersomnolence may adversely aﬀect the
patient’s ability to re-emerge from anesthesia.
Include premorbid cognitive or intellectual dysfunc-
tion as part of preoperative assessment preopera-
tively (if nonemergency intervention) because these
manifestations along with preoperative sleep depri-
vation can complicate the patient’s immediate
postoperative care and long-term recovery.
s Most serious complications occur in the postanes-
thesia period.
s See full recommendations at myotonic.org/clinical-
resources.
 Respiratory symptoms
s Pulmonary complications are the leading cause of
death in DM1 patients. Clinicians must monitor issues
such as recurrent pneumonia at baseline and serially
(±6 months), with pulmonary function tests, at least
forced vital capacity (FVC).
sRefer DM1 patients with respiratory symptoms including
ineﬀective cough (normal peak expiratory cough ﬂow rate
is >270 L/min), respiratory insuﬃciency, recurrent
pulmonary infections, prominent snoring, maximal in-
spiratory pressure is <60 cm H2O or FVC values of 50%
less than predicted normal values to a pulmonologist
knowledgeable in neuromuscular disorders.
s Vaccinate for pneumonia and ﬂu; treat respiratory
infections quickly and use cough assistance and
mechanical ventilation as needed along with obtaining
consultations from respiratory therapy and pulmo-
nary medicine groups.
s Some patients will eventually require either nighttime
ventilator support or full-time ventilation. Most
patients with chronic respiratory insuﬃciency re-
spond to noninvasive ventilatory support (NIV).
Patients experiencing acute respiratory failure require
endotracheal intubation with positive pressure
ventilation.
s For chronic respiratory insuﬃciency, use supplemen-
tal oxygen with caution and in conjunction with NIV
(see Surgery, anesthesia, and pain).
sIf surgery is planned, reassess clearance capacity if needed,
possible adaptation to NIV or cough assistance.
s See full recommendations at myotonic.org/clinical-
resources.
 Cardiovascular symptoms
s Cardiac complications are the second leading cause of
death in DM1.
s The most common cardiac issues are arrhythmias
(sinus bradycardia, heart block, atrial ﬁbrillation and
ﬂutter, and ventricular tachycardia).
s Palpitations, chest pain, dyspnea, orthopnea, light-
headedness, and syncope warrant cardiac investigation.
s Signiﬁcant cardiac involvement that subsequently leads
to adverse cardiac events is often asymptomatic.
s Impulse—conduction abnormalities on a standard
12-lead ECG including sinus rate <50 BPM, PR
interval >200 ms, QRS duration >100 ms, left
anterior or posterior fascicular block, abnormal Q-
waves, atrial tachycardia, ﬁbrillation, or ﬂutter, and
ventricular arrhythmias are indicative of cardiac
involvement.
s Refer patients with cardiac symptoms, abnormal
annual or biennial ECG indicative of cardiac in-
volvement, and patients aged above 40 years without
previous cardiac evaluation to a center experienced in
DM1 care.
s Cardiology referral for all DM1 patients is reasonable
if part of a multidisciplinary program or if the
practitioners providing primary care are uncomfort-
able assessing cardiac history, examination, or ECG.
s See full recommendations at myotonic.org/clinical-
resources.
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 Pregnancy and obstetric management
s Women with DM1:
nHave increased risk of miscarriage, preterm delivery,
and respiratory insuﬃciency during pregnancy
(especially in the 3rd trimester) and failed labor
during delivery; extreme care should be taken with
analgesics and sedating anesthetic drugs (see MDF’s
Practical Suggestions for the Anesthetic Management of
a Myotonic Dystrophy Patient [myotonic.org/clinical-
resources]).
n Should consult with a high-risk obstetrics and
gynecology (OBGYN) care provider before de-
livery and obtain ongoing antenatal care.
n Fatigue rapidly during labor and are at risk of
postpartum hemorrhage, particularly after pro-
longed ﬁrst or second stage or if there has been
polyhydramnios.
n Should be induced only at direction of obstetrician
and after all necessary consultants assisting with the
delivery are notiﬁed.
s Sexually active patients with DM1:
n Should be referred to genetic counseling and family
planning services if of child-bearing age.
n Should receive parental counselling for prenatal
genetic diagnosis or discussion of preimplantation
genetic diagnosis.
s Include a pediatric or neonatal specialist present at
delivery; intensive neonatal care is recommended for
neonates that may have DM1; anticipate need for
feeding tube and ventilator support.
n Access to a pediatric or neonatal specialist is
recommended even if the fetus is known to be
unaﬀected.
s See full recommendations at myotonic.org/clinical-
resources.
Severe symptoms and conditions—Clinical
care recommendations
 Skeletal muscle weakness and rehabilitation
s Evaluate annually for:
n Swallowing and speech diﬃculties
n Mobility, balance, and falls
n Activities of daily life—including self-care
n Activities in home, school, work, and community.
s Refer to specialists, including physical therapists
(PTs), occupational therapists (OTs), speech
pathologists, dieticians, social workers, and others.
s Encourage moderate intensity (aerobic and resistance
training) exercise.
s See Role of Physical Therapy in the Assessment of
Individuals with Myotonic Dystrophy at myotonic.org/
clinical-resources.
s See full recommendations at myotonic.org/clinical-
resources.
 Skeletal muscle myotonia
sMyotonia can cause muscle stiﬀness, prolonged hand
grip, pain, and speech and swallowing diﬃculties.
s Mexiletine or other antimyotonia medications may be
considered for myotonia treatment. Mexiletine is
contraindicated for DM1 patients with cardiac in-
volvement. See full recommendations regarding
mexiletine at myotonic.org/clinical-resources for
more information on cardiac implications.
 Ocular symptoms
s Relevant eye manifestations of DM1 include cataracts
(occurring in most patients), strabismus, and other
ocular motility problems, myopia, and astigmatism in
congenital and juvenile-onset patients.
s Recommend annual eye examination, including slit-
lamp eye examination.
s Advise patient on safety measures regarding adjusting
to changes in light (from dim to bright) while driving,
especially at night, related to the eﬀects of cataracts,
and on protecting the cornea, especially as weakness
of the face (due to m. orbicularis oculi weakness) and
eye closure muscles progress.
s Surgically remove cataracts when they interfere
with activities of daily living; see Surgery, anesthe-
sia, and pain control section regarding anesthesia
risk.
s Consider ophthalmic lubricants for dry eye, typically
caused by m. orbicular oculi weakness aﬀecting eyelids
and cornea.
s Consider eyelid crutches before surgery for ptosis (due
to m. levator palpebrae weakness); see Surgery,
anesthesia, and pain control.
s See full recommendations at myotonic.org/clinical-
resources.
 Gastrointestinal symptoms
s Ask about problems with chewing, swallowing,
drooling, reﬂux, bloating, abdominal pain, bowel
movement frequency and characteristics, diarrhea,
and incontinence.
s Physical examination should include abdominal
palpation, including around gall bladder, and rectal
examination for anal sphincter spasm and dyssynergic
defecation for symptomatic patients.
s DM1 patients are at risk for pseudo-obstruction and
experience other problems that may cause actual
obstruction of small or large intestine, including
endometriosis, acute gallbladder inﬂammation, rup-
tured ovarian cysts, sigmoid volvulus. Monitor
potential obstructions to determine whether they
are pseudo or actual and treat accordingly.
s Nonmedical interventions:
n High-ﬁber diet for diarrhea or constipation; increase
water intake
n Nutritional supplement for weight loss, weight gain,
or dysphagia
n Dysphagia therapy referral for oral pharyngeal
dysphagia.
s Medical interventions:
n Loperamide for diarrhea control
n Laxatives for constipation
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 First-line therapy: MiraLAX, Senna, Ducusate,
or Linaclotide
 Second-line therapy: Bisacodyl, Lubiprostone,
Linaclotide
n Avoid oils—if the above fails, refer out for anal
manometry
n Metoclopramide for gastroparesis, pseudo-
obstruction, reﬂux
n Antibiotics for bacterial overgrowth-induced di-
arrhea (based on breath testing)
n Enteral feeding only for recurring pneumonia or
severe dysphagia causing weight loss or causing
inability to swallow safely without recurrent
aspiration
n Mexiletine can be considered to treat diarrhea or
constipation. Mexiletine is contraindicated for
DM1 patients with cardiac involvement. See full
recommendations regarding mexiletine at myo-
tonic.org/clinical-resources for more information
on cardiac implications.
s See full recommendations at myotonic.org/clinical-
resources.
 Neuropsychiatric symptoms
s Advise patients that DM1 is also a “brain disorder”
that can involve cognitive deﬁcits and changes in
cognition over time.
s Include psychiatric and behavioral examination at
baseline, and during regularly scheduled follow-up
appointments or when symptoms appear; consider
baseline MRI to assess DM1-related abnormalities
(e.g., ﬂuid-attenuated inversion recovery hyperinten-
sities, particularly in the temporal poles, and dilated
perivascular spaces, often colocalizing) and track over
time.
s Refer patients with psychiatric or behavioral disorders,
those with late-onset phenotype, and patients with
cognitive complaints to mental health care pro-
fessional for testing and follow-up; patients may have
limited insight into these issues—consider input from
partners and family members as appropriate.
s DM1 patients with a late-onset phenotype can exhibit
fast decline in certain cognitive functions.
s See full recommendations at myotonic.org/clinical-
resources.
 Psychosocial symptoms
s Assess patient’s social circumstances in household;
consider and be aware of possible child neglect, acute
ﬁnancial need, unsafe driving, unsafe or unsanitary
home; refer to social services, support programs, and
organizations.
 Excessive daytime sleepiness (EDS) symptoms
s Assess for EDS with the Epworth Sleepiness Scale or
a similar standardized questionnaire instrument;
prescribe sleep study if sleep disturbance is suspected.
s Monitor periodic limb movements (muscle activity
during sleep), as well as EEG, and respiratory
measures during sleep study to assess possible
obstructive sleep apnea and CNS mediated sleep
apnea.
s Refer to a pulmonologist and/or sleep specialist if EDS
scores are positive on scales.
s Question patients re: alcohol or caﬀeine consumption,
medications, and sleep habits for contribution to EDS.
s Evaluate the eﬀect of possible respiratory muscle
weakness (FVC value sitting and supine) on the
presence of EDS.
s If nocturnal or daytime hypoventilation is suspected,
consider noninvasive positive pressure ventilation,
and refer to a pulmonologist with experience in
neuromuscular diseases re: possible need for NIV
launching.
s Consider modaﬁnil for treatment if coexisting CNS
alteration is suspected as the cause of EDS.
s Consider cognitive behavioral therapy or behavioral
therapy for apathy; also help treat fatigue; psychos-
timulant treatment can be considered if apathy is
associated with an impairing level of fatigue or EDS.
s See full recommendations at myotonic.org/clinical-
resources.
 Endocrine and metabolic symptoms
s Follow criteria from the American Diabetes Associa-
tion re: the type of initial testing to obtain: typically,
fasting blood glucose or HbA1c and if symptomatic
diabetes is suspected.
s Consider formal glucose tolerance testing to monitor
glucose control in patients; request serial measurement
of HbA1c and fasting plasma glucose annually and
coordinate care with a diabetes specialist as necessary.
s Consider treating insulin resistance with lifestyle
changes in diet and exercise.
s Measure liver and bilirubin levels at baseline and
annually; chronic liver enzyme elevation is typical and
does not necessarily indicate the need for obtaining
a liver biopsy.
s Request thyroid stimulating hormone and circulating
thyroid hormone (thyroid-stimulating hormone
[TSH] and Free T4) level tests at baseline and at
least every 3 years; more frequently if indicated.
s Test for hyperlipidemia through serum blood lipid
levels at baseline and every 3 years; more frequently if
indicated. Treat hyperlipidemia per current practice.
s Sex-speciﬁc recommendations:
n Inquire about painful or irregular menstruation,
ovarian cysts, endometriosis, and reproductive
history.
n Inquire about erectile dysfunction; consider
further workup and medications to treat erectile
dysfunction. Consider possible cardiovascular
risks-side eﬀects associated with some erectile
dysfunction medications (over the counter and
prescribed).
n Inquire about infertility and family planning.
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s See full recommendations at myotonic.org/clinical-
resources.
 Tumors
s Look for pilomatrixomas (skin tumors); refer to
surgeons for safe removal.
s Train patients to detect pilomatrixomas (small, a hard
lump under the skin on the head, neck, arms, torso,
and legs).
s Follow general population cancer screening guidelines,
particularly for breast, testicular, cervical, and colon
cancer.
s Evaluate suspicious new CNS, abdominopelvic, and
thyroid symptoms for possible cancer; consider
cancers of the brain, uterus, and ovary.
s See full recommendations at myotonic.org/clinical-
resources.
Conclusions
The recommendations in this study are intended to lead to
more informed and prepared clinical professionals and more
readily available and high-quality care for aﬀected families.
The Consensus-based Care Recommendations support an
international clinical trial environment that is better prepared
to successfully assess the eﬀectiveness of the potential therapies.
The 2-step methodology used to drive this consensus-building
process enabled a streamlined and relatively low-cost medical
guideline development process, resulting in care recom-
mendations available to clinicians in a timely manner.
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